Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy

Area of Science:

• Cardiovascular Research
• Molecular Medicine
• RNA Therapeutics

Background:

• Cardiovascular diseases, particularly heart failure, remain a significant global health burden with limited long-term survival rates.
• Pathological cardiac hypertrophy is a primary driver of morbidity and mortality in heart failure, lacking effective treatments.
• Non-coding RNAs (ncRNAs) are emerging as critical regulators of cardiac hypertrophy pathways, presenting novel therapeutic targets.

Purpose of the Study:

• To review the molecular mechanisms of cardiac hypertrophy.
• To explore the role of ncRNAs in cardiac hypertrophy.
• To discuss the therapeutic potential of oligonucleotide-based therapies targeting ncRNAs for heart failure.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of molecular mechanisms involving ncRNAs in cardiac hypertrophy.
• Evaluation of oligonucleotide delivery strategies and therapeutic approaches.

Main Results:

• ncRNAs play a significant role in regulating the signaling pathways of cardiac hypertrophy.
• Preclinical studies in animal models demonstrate successful amelioration of cardiac hypertrophy using ncRNA-targeting drugs.
• An antisense oligonucleotide therapy for heart failure has progressed to clinical trials.

Conclusions:

• ncRNA-targeting therapies represent a promising new avenue for treating pathological cardiac hypertrophy and heart failure.
• Advances in oligonucleotide drug delivery are crucial for overcoming current challenges and realizing the clinical potential of these therapies.
• ncRNA-based treatments for cardiac hypertrophy are becoming an increasingly attainable reality in clinical practice.